A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Areteia Therapeutics Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Respiratory Tract Diseases [C08]

Trial duration

10 Apr 2024 → 5 Nov 2025

Decision date (initial)

2024-03-18

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

Areteia Therapeutics, Inc.

External identifiers

EU CT number

2023-503693-20-01

WHO UTN

U1111-1288-9273

ClinicalTrials.gov

NCT05813288

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

The primary objective of the study is to demonstrate the efficacy of dexpramipexole in reducing severe asthma exacerbations.

Secondary objectives 3

1. To demonstrate the efficacy of dexpramipexole on pulmonary function.
2. To demonstrate the efficacy of dexpramipexole on asthma control and quality of life
3. To evaluate the effect of dexpramipexole on blood eosinophils

Conditions and MedDRA coding

Severe eosinophilic asthma

Study design 3 periods

Regulatory references

Scientific advice from competent authorities

European Medicines Agency

EMA paediatric investigation plan (PIP)

EMEA-003328-PIP01-22

Plan to share IPD

Yes

IPD plan description

Sponsor will share participant’s coded data with other companies that help Areteia Therapeutics Inc. conduct this study: Representatives of the Sponsor (including the contract research organization working with the Sponsor, monitors, third party vendors, and auditors), Advisory boards and institutional review boards/ethical committees, National health authorities, regulatory authorities and data protection authorities ensuring compliance with applicable laws, within and outside of the European Union/European Economic Area.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 11

1. Signed informed consent form and assent form, as appropriate.
2. Male or female ≥18 years of age at Screening Visit 1.
3. Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
4. Eosinophil count of ≥0.30x10^9/L at Screening Visit 1. If the initial value is between0.250x10^9/L to 0.299x10^9/L, then this may be repeated once at an unscheduled visit (priorto Screening Visit 2).
5. Treatment of asthma, participants must satisfy all the below (items a to c): a.Participants who have received asthma controller medication with medium orhigh dose ICS (≥500 μg/day fluticasone propionate dry powder formulation dailyor clinically comparable, per GINA 2021) on a regular basis for at least12 months prior to Screening Visit 1. Equivalent medium and high dose ICSdoses are detailed in Appendix C. b.Documented treatment with a stable dose of either medium or high dose ICS forat least 3 months prior to Screening Visit 1. The ICS may be contained within anICS/LABA combination product. As noted in Section 5.2.2, daily oralcorticosteroids are an allowed concomitant medication; participants on daily oralcorticosteroids must be on a stable dose for 3 months before Screening Visit 1. c.Use of one or more additional daily maintenance asthma controller medicationsaccording to standard practice of care is required; eg, LABA, leukotrieneantagonist, theophylline, long-acting muscarinic antagonists. Use of a stable doseof any additional asthma controller medications must be documented for at least3 months prior to Screening Visit 1.
6. Pre-BD FEV1 ≥40% and <80% of predicted at Screening Visit 2.
7. Variable airflow obstruction documented with at least one of the following criteria: a.Bronchodilator reversibility at Screening Visit 2, as evidenced by ≥12% and≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg(four puffs) of albuterol/salbutamol. Participants who do not meet thebronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mLreversibility may repeat the reversibility spirometry assessment once during theScreening period, at an unscheduled visit at least 7 days prior to baseline. b. Bronchodilator reversibility, using the criteria above, documented in the past 24 months prior to Screening Visit 1 or during screening. c. Peak flow variation of ≥20% over a 2-week period, documented in the past 24 months prior to Screening Visit 1 or during screening. d. Airflow variability in clinic FEV1 ≥20% between two consecutive clinic visits, documented in the past 24 months prior to Screening Visit 1 or during screening. e. Airway hyperresponsiveness (provocative concentration causing a 20% fall in FEV1 of methacholine <8 mg/mL, or other clinically relevant bronchoprovocation testing) documented in the past 24 months prior to Screening Visit 1.
8. ACQ-6 ≥1.5 at Screening Visit 2.
9. Documented history of at least two asthma exacerbations requiring treatment with systemic corticosteroids (intramuscular, intravenous, or oral) within the past 12-month period prior to Screening Visit 1.
10. Negative urine pregnancy test for women of childbearing potential (WOCBP) at the Screening and Baseline visits.
11. WOCBP (after menarche) must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit (refer to Section 8.3.3.1 for details): a. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel IUS, or oral contraceptive. OR b. Two protocol acceptable methods of contraception in tandem. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 or more months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: c. Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone (FSH) levels in the postmenopausal range. d. Women ≥50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment.

Exclusion criteria 30

1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids) at any time from 4 weeks prior to Screening Visit 1. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening Visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status.
2. Current diagnosis of diseases which may confound interpretation of this study’s findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis).
3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1.
4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long-acting anti-IL-5) in the past 12 months.
5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. Monoclonal antibody therapies should not be delayed or excluded for the sole purpose of inclusion in this clinical trial.
6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline.
7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1.
8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the coming year.
9. Weight <40 kg at Screening Visit 2.
10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of >10 pack-years. Smoking includes tobacco, vaping, and/or marijuana use.
11. Known or suspected alcohol or drug abuse
12. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to the Baseline Visit despite anti-hypertensive therapy.
13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy, and/or systemic therapy during the 5 years prior to the Baseline Visit.
14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C or positive serology at Screening Visit 2 (in EU countries).
15. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1 that has not been treated with or has failed to respond to SoC therapy.
16. Medical or other condition likely to interfere with participant’s ability to undergo study procedures, adhere to visit schedule, or comply with study requirements.
17. Known or suspected noncompliance with medication.
18. Unwillingness or inability to follow the procedures outlined in the protocol.
19. Absolute neutrophil count (ANC) <2.000x10^9/L at Screening Visit 1 or Screening Visit 2.
20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula
21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%.
23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit.
24. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation.
25. History of long QT syndrome.
26. Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at Screening Visit 2 QTcF ≥480 ms for participants with bundle branch block.
27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including resting heart rate <45 beats per minute (bpm) or >100 bpm.
28. Pregnant women or women breast feeding
29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
30. Allergy or hypersensitivity to dexpramipexole or any of its components.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Annualized rate of severe asthma exacerbations (AAER) over 52 weeks.

Secondary endpoints 3

1. Pre-BD FEV1, absolute change from baseline, averaged across visits at Weeks 36, 44, and 52.
2. Asthma Control Questionnaire-6 (ACQ-6), change from baseline, averaged across visits at Weeks 36, 44, and 52.
3. Standardized version of the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12), change from baseline to Week 52.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Placebo 1

Auxiliary 7

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Areteia Therapeutics Inc.

Sponsor organisation

Areteia Therapeutics Inc.

Address

1200 Morris Turnpike Suite 3005

City

Short Hills

Postcode

07078-2766

Country

United States

Scientific contact point

Organisation

Areteia Therapeutics Inc.

Contact name

Andrew Friedman

Public contact point

Organisation

Areteia Therapeutics Inc.

Contact name

Andrew Friedman

Third parties 14

Locations

9 EU/EEA countries · 70 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Urgent safety measures 1 · Art. 54 CTR

Corrective measures 1 · Art. 77 CTR

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 234 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

28 submissions — initial application plus substantial / non-substantial modifications